{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:48:53Z","timestamp":1785908933144,"version":"3.56.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031022","name":"Center for Cancer Research","doi-asserted-by":"publisher","award":["Z0A-BC-010816"],"award-info":[{"award-number":["Z0A-BC-010816"]}],"id":[{"id":"10.13039\/100031022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004368","name":"Colgate-Palmolive","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005345","name":"American Association for Dental, Oral, and Craniofacial Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005345","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.cllc.2026.04.005","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T20:34:44Z","timestamp":1776285284000},"page":"77-86.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Significance of Inflammatory, Cellular, and Tumor-Specific Biomarkers in Patients With Pleural and Peritoneal Mesothelioma"],"prefix":"10.1016","volume":"27","author":[{"given":"Keval","family":"Yerigeri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjistha","family":"Sengupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeevan","family":"Puthiamadathil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4012-3633","authenticated-orcid":false,"given":"Raffit","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2026.04.005_bib0001","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"Robinson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.04.005_bib0002","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMra1912719","article-title":"Perspectives on the treatment of malignant pleural mesothelioma","volume":"385","author":"Janes","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.04.005_bib0003","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S2213-2600(24)00119-X","article-title":"Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial","volume":"12","author":"Lim","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cllc.2026.04.005_bib0004","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/jso.27947","article-title":"Multisocietal consensus on the use of cytoreductive surgery and hipec for the treatment of diffuse malignant peritoneal mesothelioma: a grade approach for evidence evaluation and recommendation","volume":"131","author":"Kusamura","year":"2025","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.cllc.2026.04.005_bib0005","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.04.005_bib0006","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2026.04.005_bib0007","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cllc.2026.04.005_bib0008","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ijc.2910500308","article-title":"Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium","volume":"50","author":"Chang","year":"1992","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cllc.2026.04.005_bib0009","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0021-9258(17)42180-6","article-title":"A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5","volume":"269","author":"Yamaguchi","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cllc.2026.04.005_bib0010","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1158\/1078-0432.CCR-03-0801","article-title":"Mesothelin: a new target for immunotherapy","volume":"10","author":"Hassan","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2026.04.005_bib0011","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1158\/1078-0432.CCR-06-0472","article-title":"Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma","volume":"12","author":"Onda","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2026.04.005_bib0012","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/1078-0432.CCR-05-1477","article-title":"Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer","volume":"12","author":"Hassan","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2026.04.005_bib0013","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","article-title":"Mesothelin-family proteins and diagnosis of mesothelioma","volume":"362","author":"Robinson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2026.04.005_bib0014","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1373\/jalm.2017.025015","article-title":"Elevated serum megakaryocyte potentiating factor as a predictor of poor survival in patients with mesothelioma and primary lung cancer","volume":"3","author":"Yu","year":"2018","journal-title":"J Appl Lab Med"},{"key":"10.1016\/j.cllc.2026.04.005_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00282","article-title":"Megakaryocyte potentiating factor as a predictive biomarker for therapies against malignant mesothelioma","volume":"2018","author":"Cao","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.cllc.2026.04.005_bib0016","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1097\/JTO.0b013e318187491c","article-title":"Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer","volume":"3","author":"Schneider","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.04.005_bib0017","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1158\/1078-0432.CCR-07-0629","article-title":"Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer","volume":"13","author":"Cristaudo","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2026.04.005_bib0018","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1158\/1078-0432.CCR-10-1929","article-title":"Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden","volume":"17","author":"Creaney","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2026.04.005_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123730","article-title":"CA125 and ovarian cancer: a comprehensive review","volume":"12","author":"Charkhchi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cllc.2026.04.005_bib0020","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/s40064-016-1998-7","article-title":"Clinical significance of serum CA125 in diffuse malignant mesothelioma","volume":"5","author":"Cheng","year":"2016","journal-title":"Springerplus"},{"key":"10.1016\/j.cllc.2026.04.005_bib0021","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1245\/s10434-006-9192-8","article-title":"Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion","volume":"14","author":"Baratti","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.cllc.2026.04.005_bib0022","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1158\/1078-0432.CCR-10-2245","article-title":"High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy","volume":"16","author":"Kao","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2026.04.005_bib0023","doi-asserted-by":"crossref","first-page":"57460","DOI":"10.18632\/oncotarget.15404","article-title":"Prognostic significance of neutrophil-to-lymphocyte ratio in patients with malignant pleural mesothelioma: a meta-analysis","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cllc.2026.04.005_bib0024","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1080\/09537104.2016.1246712","article-title":"Pretreatment thrombocytosis as a significant prognostic factor in malignant mesothelioma: a meta-analysis","volume":"28","author":"Zhuo","year":"2017","journal-title":"Platelets"},{"key":"10.1016\/j.cllc.2026.04.005_bib0025","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thorax.55.9.731","article-title":"Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems","volume":"55","author":"Edwards","year":"2000","journal-title":"Thorax"},{"key":"10.1016\/j.cllc.2026.04.005_bib0026","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/SLA.0b013e3182602af4","article-title":"Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis","volume":"256","author":"Ghanim","year":"2012","journal-title":"Ann Surg"},{"key":"10.1016\/j.cllc.2026.04.005_bib0027","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1245\/s10434-014-4048-0","article-title":"The C-reactive protein\/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma","volume":"22","author":"Kinoshita","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.cllc.2026.04.005_bib0028","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1245\/s10434-018-6385-x","article-title":"The C-reactive protein\/albumin ratio is a novel significant prognostic factor in patients with malignant pleural mesothelioma: a retrospective multi-institutional study","volume":"25","author":"Takamori","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.cllc.2026.04.005_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.suronc.2022.101813","article-title":"Prognostic values of preoperative C-reactive protein, albumin, and neutrophil ratios in patients with malignant pleural mesothelioma who underwent extrapleural pneumonectomy","volume":"43","author":"Okita","year":"2022","journal-title":"Surg Oncol"},{"key":"10.1016\/j.cllc.2026.04.005_bib0030","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/bjc.2013.815","article-title":"Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma","volume":"110","author":"Ghanim","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2026.04.005_bib0031","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1002\/cncr.28875","volume":"120","author":"Hassan","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2026.04.005_bib0032","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin Immunotherapy for cancer: ready for prime time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.04.005_bib0033","article-title":"Mesothelin biology and the evolving landscape of targeted immunotherapy","volume":"34","author":"Boisgard","year":"2026","journal-title":"Mole Ther Oncol"},{"key":"10.1016\/j.cllc.2026.04.005_bib0034","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A Phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the Anti-PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2026.04.005_bib0035","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.cllc.2026.04.005_bib0036","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-023-02452-y","article-title":"Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1\/2 trial interim results","volume":"29","author":"Hassan","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.cllc.2026.04.005_bib0037","doi-asserted-by":"crossref","first-page":"46425","DOI":"10.18632\/oncotarget.17436","article-title":"Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis","volume":"8","author":"Tian","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cllc.2026.04.005_bib0038","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/1759-7714.15264","article-title":"Circulating SMRP and CA-125 before and after pleurectomy decortication for pleural mesothelioma","volume":"15","author":"Paajanen","year":"2024","journal-title":"Thoracic Cancer"},{"key":"10.1016\/j.cllc.2026.04.005_bib0039","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.3390\/cells12162048","article-title":"Chronic inflammation, oxidative stress and metabolic plasticity: three players driving the pro-tumorigenic microenvironment in malignant mesothelioma","volume":"12","author":"Fiorilla","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.cllc.2026.04.005_bib0040","first-page":"516","article-title":"Inflammation in malignant mesothelioma - friend or foe?","volume":"1","author":"Linton","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1016\/j.cllc.2026.04.005_bib0041","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.3390\/cancers17081371","article-title":"The mesothelioma systemic inflammation score is independently associated with overall survival and predicts benefit of multimodality treatment in pleural mesothelioma","volume":"17","author":"Mosleh","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cllc.2026.04.005_bib0042","doi-asserted-by":"crossref","first-page":"12611","DOI":"10.1073\/pnas.1006542107","article-title":"Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation","volume":"107","author":"Yang","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cllc.2026.04.005_bib0043","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/bjc.2014.478","article-title":"Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales","volume":"111","author":"Linton","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2026.04.005_bib0044","series-title":"StatPearls (Internet)","article-title":"Physiology, acute phase reactants","author":"Gulhar","year":"2025"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:20:40Z","timestamp":1785907240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426000562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1525730426000562"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.04.005","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Significance of Inflammatory, Cellular, and Tumor-Specific Biomarkers in Patients With Pleural and Peritoneal Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}